Platinum Investment Management Ltd. purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 19,138 shares of the biopharmaceutical company’s stock, valued at approximately $1,598,000. Several other hedge funds have also made changes to their positions in the company. Seven Eight Capital LP purchased […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) Director Robert Arthur Harrington sold 1,580 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $48.64, for a total transaction of $76,851.20. Following the sale, the director now directly owns 15,541 shares in the company, valued […]
Rafferty Asset Management LLC lifted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 6.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,275 shares of the biopharmaceutical company’s stock after purchasing an additional 16,353 shares during the quarter. Rafferty Asset Management LLC’s […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective lowered by Truist Financial from $86.00 to $70.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on CYTK. JMP Securities cut their price […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target decreased by JMP Securities from $106.00 to $78.00 in a research note issued to investors on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biopharmaceutical company’s stock. CYTK has been the subject of a number of other reports. Mizuho dropped their […]